Supplementary Figure 6: Sros1 maintains the expression of STAT1 without affecting protein stability.

a, qRT−PCR analysis of Sros1 from Sros1−overexpressing or control RAW264.7 cells. b−c, Immunoblot analysis and quantification analysis of total STAT1 and β−actin in Sros1−silenced PMs (b), or Sros1−overexpressing RAW264.7 cells (c) and control cells. Cells were treated with 10 µg/ml CHX for the indicated times. d, Relative distributions of Stat1 mRNA populations across each fraction in the sucrose gradient were determined and normalized to the sum of the mRNA signal across all gradient fractions in Sros1−silenced PMs. x axis, fraction number. e, qRT−PCR analysis of Sros1 and Stat1 mRNA in PMs after L.m. stimulated for indicated times. f. Changes of total STAT1 protein in PMs transfected with siRNAs for functional screening. Ddx17−1 and Ddx17−2 represent different siRNAs targeting to distinct transcripts of Ddx17. g, Immunoblot analysis and quantification analysis of phosphorylated (p−) or total STAT1, total CAPRIN1 or β−Actin in siRNA transfected PMs after treatment with IFN−γ (50 U/ml) for the indicated times. h, qRT−PCR analysis of Sros1 and Stat1 mRNA in siRNA transfected PMs. Data are representative of three independent experiments (b,c,g) or three independent experiments with n=3 biological replicates (a−h; shown as mean and s.e.m.). Individual data points represent individual biological replicates. *P<0.05, **P<0.01,***P<0.001, two−tailed unpaired Student’s t−test.